Overview

Mifepristone (RU-486) in Androgen Independent Prostate Cancer

Status:
Completed
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the effects (good and bad) that mifepristone has on patients with androgen independent prostate cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Beth Israel Deaconess Medical Center
Brigham and Women's Hospital
Georgetown University
Massachusetts General Hospital
Treatments:
Androgens
Mifepristone